EMA Withdrawn: Sonata (zaleplon) — Meda AB

View source ↗

Summary

The EMA has withdrawn Sonata (zaleplon) from the market in Europe (MAH: Meda AB) with a decision dated 03/07/2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sleep Initiation and Maintenance Disorders

Drugs mentioned

• Sonata (zaleplon)

Snippet

Status: Withdrawn. Therapeutic area: Sleep Initiation and Maintenance Disorders. MAH: Meda AB. Decision date: 03/07/2015